parkinsonian disorders


Summary: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Top Publications

  1. ncbi Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism
    A Raz
    Department of Physiology, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel
    J Neurosci 20:8559-71. 2000
  2. ncbi Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders
    Irene Litvan
    Movement Disorder Program, University of Louisville, KY 40205, USA
    Mov Disord 18:467-86. 2003
  3. ncbi Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
    Alexander Zimprich
    Department of Neurodegenerative Disease, Hertie Institute for Clinical Brain Research, University of Tubingen, 72076 Tubingen, Germany
    Neuron 44:601-7. 2004
  4. ncbi Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
    D C Wu
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 22:1763-71. 2002
  5. ncbi Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase
    Alfredo Ramirez
    Institute of Human Genetics, University of Cologne, 50931 Cologne, Germany
    Nat Genet 38:1184-91. 2006
  6. pmc Second consensus statement on the diagnosis of multiple system atrophy
    S Gilman
    Department of Neurology, University of Michigan, 300 N Ingalls St, 3D15, Ann Arbor, MI 48109 5489, USA
    Neurology 71:670-6. 2008
  7. ncbi The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
    Andrew J Hughes
    The United Kingdom Parkinson s Disease Society Brain Research Centre, Institute of Neurology, London, UK
    Brain 125:861-70. 2002
  8. ncbi Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway
    Ronald Deumens
    Department of Psychiatry and Neuropsychology, Brain and Behavior Institute, 6200 MD Maastricht, The Netherlands
    Exp Neurol 175:303-17. 2002
  9. pmc Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models
    Antony A Cooper
    School of Biological Sciences, University of Missouri Kansas City, Kansas City, MO 64110, USA
    Science 313:324-8. 2006
  10. pmc NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
    Du Chu Wu
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 100:6145-50. 2003

Detail Information

Publications331 found, 100 shown here

  1. ncbi Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism
    A Raz
    Department of Physiology, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel
    J Neurosci 20:8559-71. 2000
    ..The results illustrate that MPTP treatment changes the pattern of activity and synchronization in the GPe and GPi. These changes are related to the symptoms of Parkinson's disease and especially to the parkinsonian tremor...
  2. ncbi Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders
    Irene Litvan
    Movement Disorder Program, University of Louisville, KY 40205, USA
    Mov Disord 18:467-86. 2003
    As there are no biological markers for the antemortem diagnosis of degenerative parkinsonian disorders, diagnosis currently relies upon the presence and progression of clinical features and confirmation depends on neuropathology...
  3. ncbi Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
    Alexander Zimprich
    Department of Neurodegenerative Disease, Hertie Institute for Clinical Brain Research, University of Tubingen, 72076 Tubingen, Germany
    Neuron 44:601-7. 2004
    ..Hence, LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism...
  4. ncbi Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
    D C Wu
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 22:1763-71. 2002
    ..This study demonstrates that microglial-related inflammatory events play a significant role in the MPTP neurotoxic process and suggests that minocycline may be a valuable neuroprotective agent for the treatment of PD...
  5. ncbi Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase
    Alfredo Ramirez
    Institute of Human Genetics, University of Cologne, 50931 Cologne, Germany
    Nat Genet 38:1184-91. 2006
    ..Our findings link a class of proteins with unknown function and substrate specificity to the protein networks implicated in neurodegeneration and parkinsonism...
  6. pmc Second consensus statement on the diagnosis of multiple system atrophy
    S Gilman
    Department of Neurology, University of Michigan, 300 N Ingalls St, 3D15, Ann Arbor, MI 48109 5489, USA
    Neurology 71:670-6. 2008
    ..Since then, clinical, laboratory, neuropathologic, and imaging studies have advanced the field, requiring a fresh evaluation of diagnostic criteria. We held a second consensus conference in 2007 and present the results here...
  7. ncbi The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
    Andrew J Hughes
    The United Kingdom Parkinson s Disease Society Brain Research Centre, Institute of Neurology, London, UK
    Brain 125:861-70. 2002
    ..This study implies that neurologists with particular expertise in the field of movement disorders may be using a method of pattern recognition for diagnosis which goes beyond that inherent in any formal set of diagnostic criteria...
  8. ncbi Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway
    Ronald Deumens
    Department of Psychiatry and Neuropsychology, Brain and Behavior Institute, 6200 MD Maastricht, The Netherlands
    Exp Neurol 175:303-17. 2002
    ..The choice of the behavioral parameters determines the use of unilateral or bilateral lesions, although it is obvious that the bilateral model mimics the human situation more closely...
  9. pmc Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models
    Antony A Cooper
    School of Biological Sciences, University of Missouri Kansas City, Kansas City, MO 64110, USA
    Science 313:324-8. 2006
    ..Thus, synucleinopathies may result from disruptions in basic cellular functions that interface with the unique biology of particular neurons to make them especially vulnerable...
  10. pmc NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
    Du Chu Wu
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 100:6145-50. 2003
    ..This study supports a critical role for NADPH-oxidase in the pathogenesis of PD and suggests that targeting this enzyme or enhancing extracellular antioxidants may provide novel therapies for PD...
  11. ncbi Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP
    Andreas Schober
    Department of Neuroanatomy and IZN, University of Heidelberg, Im Neuenheimer Feld 307, 69120 Heidelberg, Germany
    Cell Tissue Res 318:215-24. 2004
    ..The new genetic and environmental toxin models of PD ( $132#g. rotenone, paraquat, maneb) are discussed elsewhere in this "special issue."..
  12. ncbi Molecular pathways of neurodegeneration in Parkinson's disease
    Ted M Dawson
    Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Science 302:819-22. 2003
    ..Strategies aimed at restoring complex I activity, reducing oxidative stress and alpha-synuclein aggregation, and enhancing protein degradation may hold particular promise as powerful neuroprotective agents in the treatment of PD...
  13. ncbi The familial Parkinsonism gene LRRK2 regulates neurite process morphology
    David Macleod
    Departments of Pathology and Neurology, Center for Neurobiology and Behavior and Taub Institute, Columbia University, College of Physicians and Surgeons 15 403, 630 West 168th Street, New York, New York 10032, USA
    Neuron 52:587-93. 2006
    ..Neurons that express PD-associated LRRK2 mutations additionally harbor prominent phospho-tau-positive inclusions with lysosomal characteristics and ultimately undergo apoptosis...
  14. ncbi FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome
    A Di Fonzo
    Department of Clinical Genetics, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Neurology 72:240-5. 2009
    ..Very recently, a locus was mapped in a single family with an overlapping phenotype, and an FBXO7 gene mutation was nominated as the likely disease cause...
  15. pmc Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia
    Manju A Kurian
    Department of Medical and Molecular Genetics, University of Birmingham School of Medicine, Institute of Biomedical Research, Birmingham, United Kingdom
    J Clin Invest 119:1595-603. 2009
    ..Identification of the molecular basis of IPD suggests SLC6A3 as a candidate susceptibility gene for other movement disorders associated with parkinsonism and/or dystonic features...
  16. ncbi Characterization of PLA2G6 as a locus for dystonia-parkinsonism
    Coro Paisan-Ruiz
    Laboratory of Neurogenetics, National Institute on Aging, Intramural Research Program, National Institutes of Health, Bethesda, MD, USA
    Ann Neurol 65:19-23. 2009
    ..Although many recessive loci causing parkinsonism dystonia have been identified, these do not explain all cases of the disorder...
  17. ncbi Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations
    Coro Paisan-Ruiz
    Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom
    Mov Disord 25:1791-800. 2010
    ..These data suggest that these four genes account for many cases of Levodopa responsive parkinsonism with pyramidal signs cases formerly categorized clinically as pallido-pyramidal syndrome...
  18. ncbi Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations
    Marcelo Machado Ferro
    Departamento de Farmacologia, Universidade Federal do Parana, Curitiba, Brazil
    J Neurosci Methods 148:78-87. 2005
    ..The picture of mild motor effects and robust impairment of habit learning and spatial working memory observed in MPTP-lesioned rats models the early phase of Parkinson's disease...
  19. ncbi Parkinsonism, Lrrk2 G2019S, and tau neuropathology
    A Rajput
    Division of Neurology, University of Saskatchewan and Saskatoon Health Region, Saskatoon, Saskatchewan, Canada
    Neurology 67:1506-8. 2006
    ..Intriguingly, we observe no evidence of a direct interaction between either the tau or alpha-synuclein protein with Lrrk2...
  20. pmc Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death
    Janet Ugolino
    Biochemistry and Molecular Biology Graduate Program, University of Maryland, Baltimore, 725 West Lombard Street, Baltimore, MD 21201, USA
    Hum Mol Genet 20:3565-77. 2011
    ..Lastly, we show Atp13a2 mutants have increased cytotoxicity and predispose cells to ER-stress-induced cell death. These results provide new insight into the properties of wild-type and mutant Atp13a2 proteins involved in KRS...
  21. pmc Automated, high accuracy classification of Parkinsonian disorders: a pattern recognition approach
    Andre F Marquand
    Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, King s College London, London, United Kingdom
    PLoS ONE 8:e69237. 2013 demonstrates that automated analysis of structural MRI can accurately predict diagnosis in individual patients with Parkinsonian disorders, and identifies distinct patterns of regional atrophy particularly useful for this process.
  22. ncbi Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease
    T Breidert
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Pitie Salpetriere, Paris, France
    J Neurochem 82:615-24. 2002
    ..Since pioglitazone affects primarily the SNpc in our model, different PPARgamma-independent mechanisms may regulate glial activation in the dopaminergic terminals compared with the dopaminergic cell bodies after acute MPTP intoxication...
  23. ncbi Methamphetamine-induced neurotoxicity: the road to Parkinson's disease
    Bessy Thrash
    Department of Pharmacological Sciences, Harrison School of Pharmacy, Auburn University, 4306 Walker building, Auburn, AL 36849, USA
    Pharmacol Rep 61:966-77. 2009
    ..In addition, this review evaluates the possible neuroprotective mechanisms of certain drugs against methamphetamine-induced toxicity...
  24. pmc Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress
    Raymond H Kim
    Campbell Family Institute for Breast Cancer Research, Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada M5G 2C1
    Proc Natl Acad Sci U S A 102:5215-20. 2005
    ..Thus, DJ-1 protects against neuronal oxidative stress, and loss of DJ-1 may lead to Parkinson's disease by conferring hypersensitivity to dopaminergic insults...
  25. ncbi Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease
    J L Tillerson
    Institute for Neuroscience, University of Texas at Austin, Austin, TX, 78712, USA
    Neuroscience 119:899-911. 2003
    ..These results demonstrate that exercise following nigrostriatal damage ameliorates related motor symptoms and neurochemical deficits in rodent models of PD...
  26. ncbi Optical deconstruction of parkinsonian neural circuitry
    Viviana Gradinaru
    Department of Bioengineering, Stanford University, Stanford, CA 94305, USA
    Science 324:354-9. 2009
  27. ncbi Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism
    Vincenzo Bonifati
    Genetic Epidemiologic Unit, Department of Clinical Genetics, Department of Epidemiology and Biostatistics, Erasmus Medical Center Rotterdam, Post Office Box 1738, 3000 DR Rotterdam, Netherlands
    Science 299:256-9. 2003
    ..Elucidating the physiological role of DJ-1 protein may promote understanding of the mechanisms of brain neuronal maintenance and pathogenesis of Parkinson's disease...
  28. ncbi Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease
    R K Chaturvedi
    Developmental Toxicology Division, Industrial Toxicology Research Centre, Post Box 80, M G Marg Lucknow 226001, India
    Neurobiol Dis 22:421-34. 2006
  29. ncbi Ocular motor abnormalities in Parkinsonian syndromes
    Elmar H Pinkhardt
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, Ulm, Germany
    Parkinsonism Relat Disord 17:223-30. 2011
  30. ncbi Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations
    Maria I Behrens
    Departamento de Neurologia y Neurocirugia, Hospital Clinico Universidad de Chile, Santiago, Chile
    Mov Disord 25:1929-37. 2010
    ..The marked caudate and lenticular nucleus T2*-hypointensity suggests that KRS might belong to the family of neurodegenerative diseases associated with brain iron accumulation...
  31. ncbi Neuroanatomy and pathology of sporadic Parkinson's disease
    Heiko Braak
    Institute for Clinical Neuroanatomy, Goethe University Frankfurt, Germany
    Adv Anat Embryol Cell Biol 201:1-119. 2009
    ..Against the background of the normal morphology and anatomy, the authors analyze the pathoanatomy of sPD in the nervous system at various neuropathological stages and summarize the potential functional consequences of the lesions...
  32. ncbi Complex I: inhibitors, inhibition and neurodegeneration
    A H V Schapira
    Department of Clinical Neurosciences, Institute of Neurology, Rowland Hill St, London NW3 2PF, UK
    Exp Neurol 224:331-5. 2010
    ..It is possible that these compounds may contribute to the pathogenesis of neurodegenerative disorders, although further work must be done to confirm their potential participation in pathogenesis...
  33. pmc Spinal cord stimulation restores locomotion in animal models of Parkinson's disease
    Romulo Fuentes
    Department of Neurobiology, Duke University Medical Center, Durham, NC 27710, USA
    Science 323:1578-82. 2009
    ..We propose that dorsal column stimulation might become an efficient and less invasive alternative for treatment of Parkinson's disease in the future...
  34. ncbi Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function
    James A Olzmann
    Departments of Pharmacology, Biochemistry, and Neurology, Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322 3090, USA
    J Biol Chem 279:8506-15. 2004
    ..Together these findings provide insights into the molecular mechanism by which loss-of-function mutations in DJ-1 lead to Parkinson's disease...
  35. ncbi Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease
    Göran Bertilsson
    NeuroNova AB, Stockholm, Sweden
    J Neurosci Res 86:326-38. 2008
  36. ncbi Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents
    M A Hellmann
    Laboratory of Neurosciences, Felsenstein Medical Research Center, Department of Neurology, Rabin Medical Center, Beilinson Campus, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva 49100, Israel
    Neurosci Lett 395:124-8. 2006
    ..In conclusion, we demonstrate that 6-OHDA-induced damage increases the viability of transplanted MSC and attracts these cells from the opposite hemisphere...
  37. ncbi MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats
    Nadine Jonkers
    Department of Pharmaceutical Chemistry and Drug Analysis, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
    Brain Res 926:149-55. 2002
    ..The suppression of this increase by prior administration of MK801 could represent a neuroprotective effect...
  38. pmc DCTN1 mutations in Perry syndrome
    Matthew J Farrer
    Division of Neurogenetics, Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, USA
    Nat Genet 41:163-5. 2009
    ..Our findings show that DCTN1 mutations, previously associated with motor neuron disease, can underlie the selective vulnerability of other neuronal populations in distinct neurodegenerative disorders...
  39. ncbi Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice
    Masatoshi Inden
    Department of Neurobiology, Kyoto Pharmaceutical University, Japan
    Biol Pharm Bull 34:92-6. 2011
    ..Thus, this protocol for chronic administration of rotenone at 30 mg/kg for 56 d is more useful for understanding the mechanism of DA neurodegeneration...
  40. ncbi Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression
    Yun Ju C Song
    Prince of Wales Medical Research Institute and the University of New South Wales, Barker Street, Randwick, Sydney, Australia
    J Neuropathol Exp Neurol 68:1073-83. 2009
    ..These heterogeneous astroglial responses in PD, MSA, PSP, and CBD indicate distinct underlying pathogenic mechanisms in each disorder...
  41. ncbi Dopamine depletion impairs precursor cell proliferation in Parkinson disease
    Günter U Höglinger
    INSERM U289 Hôpital de la Salpetrière, F 75651 Paris, France
    Nat Neurosci 7:726-35. 2004
    ..These observations suggest that the generation of neural precursor cells is impaired in Parkinson disease as a consequence of dopaminergic denervation...
  42. ncbi Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry
    Martin Köllensperger
    Clinical Department of Neurology, Innsbruck Medical University, Austria
    Mov Disord 25:2604-12. 2010
    ..The observed differences in diagnostic and therapeutic management including lack of therapy for dysautonomia emphasize the need for future guidelines in these areas...
  43. ncbi Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice
    Wonsuk Yang
    Department of Neurology, The University of Chicago, IL 60637, USA
    Hum Mol Genet 16:2900-10. 2007
    ..In conclusion, this study raises the possibility that environmental and genetic factors might cooperatively involve the mechanisms underlying proteasome impairment in PD brains...
  44. ncbi Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia
    Incarnation Aubert
    Centre National de la Recherche Scientifique Unite Mixte de Recherche 5541, Bordeaux Cedex, France
    Ann Neurol 57:17-26. 2005
    ..Our data suggest that levodopa-induced dyskinesia results from increased dopamine D(1) receptor-mediated transmission at the level of the direct pathway...
  45. ncbi Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum
    Y He
    Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Brain Res 909:187-93. 2001
    ..All these results suggest that microglial activation may be involved in the nigral cell degeneration in 6-OHDA induced parkinsonian mice...
  46. ncbi Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study
    Nin P S Bajaj
    Department of Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK
    J Neurol Neurosurg Psychiatry 81:1223-8. 2010
    ..This study examines the clinical accuracy of movement disorder specialists in distinguishing tremor dominant Parkinson's disease (TDPD) from other tremulous movement disorders by the use of standardised patient videos...
  47. ncbi Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label contr
    Andreas R Kupsch
    Department of Neurology, University Medicine Berlin, Berlin, Germany
    J Neurol Neurosurg Psychiatry 83:620-8. 2012
  48. pmc The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders
    Timothy Rittman
    Department of Clinical Neurosciences, University of Cambridge, Herchel Smith Building, Forvie Site, Addenbrooke s Hospital Site, Robinson Way, Cambridge CB2 0SZ, UK
    J Neurol Neurosurg Psychiatry 84:544-51. 2013
    ..We assessed whether the Revised Addenbrooke's Cognitive Examination (ACE-R) could differentiate between parkinsonian syndromes and reflect longitudinal changes in cognition in these disorders...
  49. ncbi [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism
    Sabine Hellwig
    Department of Neurology, University of Freiburg, Germany
    Neurology 79:1314-22. 2012
  50. ncbi Therapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone-treated parkinsonian mice
    Masatoshi Inden
    Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Yamashina ku, Kyoto, Japan
    J Neurosci Res 91:62-72. 2013
  51. ncbi The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism
    Koen Van Laere
    Division of Nuclear Medicine, University Hospital Leuven Gasthuisberg, E901, Herestraat 49, 3000 Leuven, Belgium
    Eur J Nucl Med Mol Imaging 35:1367-76. 2008
    ..As the model was developed before application of the diagnostic technique in real practice, a predictive validity assessment was performed based on data from a large nationwide patient registry in these patients...
  52. pmc Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
    J Peng
    Buck Institute for Age Research, Novato, CA 94945, USA
    Neuroscience 153:664-70. 2008
    ..Thus, MPTP-induced brain injury increases striatal neurogenesis and, in combination with FGF-2 treatment, also stimulates neurogenesis in SN...
  53. ncbi Lewy bodies and parkinsonism in families with parkin mutations
    M Farrer
    Department of Neuroscience, Mayo Clinic Jacksonville, FL, USA
    Ann Neurol 50:293-300. 2001
  54. pmc Saccades during attempted fixation in parkinsonian disorders and recessive ataxia: from microsaccades to square-wave jerks
    Jorge Otero-Millan
    Department of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona, United States of America
    PLoS ONE 8:e58535. 2013
    ..are present in most human subjects, but are prominent by their increased frequency and size in certain parkinsonian disorders and in recessive, hereditary spinocerebellar ataxias...
  55. ncbi Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats
    Francesca Cicchetti
    Centre de Recherche en Neurosciences, CHUL, RC 9800, 2705 Boulevard Laurier, Sainte Foy, QC, Canada G1V 4G2
    Neurobiol Dis 20:360-71. 2005
    ..These results indicate that exposure to PQ with or without MB induces neurodegeneration which might occur via an early inflammatory response in young adult animals...
  56. pmc Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein
    Jieqiong Tan
    State Key Laboratory of Medical Genetics, Xiangya Medical School, Central South University, Changsha, Hunan, China
    J Biol Chem 286:29654-62. 2011
    ..Our results suggest that ATP13A2 plays important roles in protecting cells against manganese cytotoxicity via regulating intracellular manganese homeostasis. The study provides a potential mechanism of KRS and parkinsonism pathogenesis...
  57. ncbi Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease
    Jinghua Jin
    Department of Pathology, School of Medicine, University of Washington, Seattle, WA 98104, USA
    Brain Res Mol Brain Res 134:119-38. 2005
    ..In addition, DJ-1 was present in the halo but not in the core of classical LBs in patients with PD. Our findings suggested that DJ-1 might play an important role in mitochondrial dysfunction, as well as LB formation in PD...
  58. ncbi Rapid response of parkinsonian tremor to STN-DBS changes: direct modulation of oscillatory basal ganglia activity?
    Christian Blahak
    Department of Neurology, Universitaetsklinikum Mannheim, University of Heidelberg, Mannheim, Germany
    Mov Disord 24:1221-5. 2009
    ..These findings support the hypothesis that STN-DBS acts by direct interference with the neurotransmission of basal ganglia networks involved in tremor...
  59. ncbi Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging
    M Baldereschi
    Italian National Research Council CNR CSFET ILSA Study, Florence, Italy
    Neurology 55:1358-63. 2000
    ..To determine the incidence of parkinsonism and PD in the Italian elderly, and to explore the relation with age and gender...
  60. ncbi Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease
    H Shimura
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Science 293:263-9. 2001
    ..These findings demonstrate a critical biochemical reaction between the two PD-linked gene products and suggest that this reaction underlies the accumulation of ubiquitinated alpha-synuclein in conventional PD...
  61. ncbi FDG PET in the differential diagnosis of parkinsonian disorders
    Thomas Eckert
    Center for Neurosciences, Institute for Medical Research, North Shore Long Island Jewish Health System, Manhasset, NY 11030, USA
    Neuroimage 26:912-21. 2005
    The differential diagnosis of parkinsonian disorders can be challenging, especially early in the disease course...
  62. ncbi Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone-induced hemiparkinsonian rats
    Nian Xiong
    Department of Neurology, Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, People s Republic of China
    Biol Blood Marrow Transplant 16:1519-29. 2010
    ..The results of this long-term study suggest that HUMSCs transplantation, 1 of the most potential treatments for Parkinson's disease, is an effective and safe approach...
  63. ncbi Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease
    E N Mangano
    Institute of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario, Canada K1S 5B6
    Neurobiol Dis 43:99-112. 2011
    ..These data suggest that peripheral GM-CSF administration might hold promise as a treatment of PD...
  64. ncbi Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach
    Martin Südmeyer
    Department of Neurology, Faculty of Medicine and University Clinic, Heinrich Heine University, Dusseldorf, Germany
    J Nucl Med 52:733-40. 2011
    ..The aim of this study was therefore to evaluate to which extent diagnostic accuracy can be increased by their combined use together with a multidimensional statistical algorithm...
  65. ncbi Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia
    Karen L Eskow Jaunarajs
    Department of Psychology, Binghamton University, State University of New York, Binghamton, New York 13902, USA
    Neuroreport 20:1265-9. 2009
    ..These findings suggest that 5-HT1B receptor stimulation directly diminishes D1 receptor-mediated dyskinesia, implicating an important target for the treatment of L-DOPA-induced dyskinesia...
  66. ncbi Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure
    Carlos Barcia
    Experimental Neurology and Neurosurgery Group, Department of Human Anatomy and Psychobiology, School of Medicine, University of Murcia, Murcia, Spain
    Glia 46:402-9. 2004
    ..These data suggest that neurodegeneration was still active despite the absence of the agent triggering cell death and that the glial reaction is associated with long-term neurodegeneration...
  67. ncbi Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging
    L Minati
    Scientific Direction Unit, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy
    AJNR Am J Neuroradiol 28:309-13. 2007
    ..We investigated the potential role of area and T1 contrast measurements in differentiating patients from controls and their age-related changes...
  68. pmc Voluntary exercise reduces the neurotoxic effects of 6-hydroxydopamine in maternally separated rats
    Musa Vuyisile Mabandla
    Department of Human Physiology, School of Medical Sciences, Faculty of Health Sciences, University of KwaZulu Natal, Durban 4000, South Africa
    Behav Brain Res 211:16-22. 2010
  69. pmc Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain
    Eri Sakata
    Department of Structural Biology and Biomolecular Engineering, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3 1 Tanabe dori, Mizuho ku, Nagoya 467 8603, Japan
    EMBO Rep 4:301-6. 2003
    ..Our findings suggest that the Arg 42 mutation induces a conformational change in the Rpn10-binding site of Ubl, resulting in impaired proteasomal binding of parkin, which could be the cause of AR-JP...
  70. ncbi BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease
    Brigitte Spinnewyn
    Ipsen Innovation, Neurology, Les Ulis, France
    Neuropharmacology 60:692-700. 2011
    ..The data demonstrate that BN82451 effectively attenuates LID and the associated molecular alterations in an animal model of PD and may represent a treatment option for managing dyskinesia...
  71. pmc Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity
    Marija Usenovic
    Department of Neurology, Harvard Medical School, Boston, MA, USA
    J Neurosci 32:4240-6. 2012
    ..Our findings implicate lysosomal dysfunction in the pathogenesis of Kufor-Rakeb syndrome and suggest that upregulation of lysosomal function and downregulation of α-synuclein represent important therapeutic strategies for this disorder...
  72. ncbi Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat
    S Singh
    Department of Physiology, Maulana Azad Medical College, New Delhi, India
    Indian J Med Res 124:419-26. 2006
    ..Therefore in the present study the effect of neuroprotectory melatonin was tested against 6-hydroxydopamine (6-OHDA) neurotoxicity for striatal dopaminergic neurons in the rat...
  73. ncbi Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions
    L Truong
    Department of Pharmacology, Institute for Biochemical Research, Bosch Building, School of Medical Sciences, University of Sydney, NSW 2006, Australia
    Behav Brain Res 169:1-9. 2006
    ..This graded model can be useful for testing potential neuroprotective compounds for PD...
  74. ncbi Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease
    Mark L Weiss
    Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas 66506, USA
    Stem Cells 24:781-92. 2006
    ..In summary, the umbilical cord matrix appears to be a rich, noncontroversial, and inexhaustible source of primitive mesenchymal stem cells...
  75. pmc Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
    Mats I Ekstrand
    Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, S 14186 Stockholm, Sweden
    Proc Natl Acad Sci U S A 104:1325-30. 2007
    ..These experiments demonstrate that respiratory chain dysfunction in DA neurons may be of pathophysiological importance in PD...
  76. ncbi Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease
    N L Khan
    Department of Molecular Neurosciences, Institute of Neurology, London School of Hygiene and Tropical Medicine, University College London, UK
    Neurology 62:1224-6. 2004
    ..3; 95% CI 12.2 to 19.5; p < 0.0001) and the parkin-negative group (mean 17.1; 95% CI 14.8 to 16.3; p < 0.0001) values. Parkin disease may be a distinct and separate entity from Parkinson disease...
  77. ncbi Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism
    D E Shan
    Neurological Institute, Taipei Veterans General Hospital, Taiwan, ROC
    Ann Neurol 50:812-5. 2001
    ..The reduction of 18F-dopa distribution in both the putamen and caudate nuclei confirmed that the nigrostriatal dopaminergic system was involved in parkinsonian patients with SCA2 mutation...
  78. ncbi Preserved myocardial [123I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: first case report
    Masahiko Suzuki
    Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan
    Mov Disord 20:634-6. 2005
    ..Although the clinical features of AR-JP are sometimes quite similar to those of late-onset idiopathic PD, 123I-MIBG myocardial scintigraphy may be a powerful tool to differentiate PD from other parkinsonian syndromes, including AR-JP...
  79. ncbi Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin
    Nicole Exner
    Center for Integrated Protein Science Munich and Adolf Butenandt Institute, Department of Biochemistry, Laboratory for Alzheimer s and Parkinson s Disease Research, Ludwig Maximilians University, 80336 Munich, Germany
    J Neurosci 27:12413-8. 2007
    ..Our results may therefore suggest that PINK1 deficiency in humans results in mitochondrial abnormalities associated with cellular stress, a pathological phenotype, which can be ameliorated by enhanced expression of parkin...
  80. ncbi Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia
    Emanuela Santini
    Department of Neuroscience, Karolinska Institutet, Retzius vag 8, 171 77 Stockholm, Sweden
    Sci Signal 2:ra36. 2009
    ..Thus, the mTORC1 signaling cascade represents a promising target for the design of anti-Parkinsonian therapies...
  81. ncbi Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
    Barbara Picconi
    Clinica Neurologica, Dipartimento di Neuroscienze, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Nat Neurosci 6:501-6. 2003
    ..These results indicate that abnormal information storage in corticostriatal synapses is linked with the development of L-DOPA-induced dyskinesia...
  82. ncbi Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism
    Gavin Hudson
    Mitochondrial Research Group, University of Newcastle upon Tyne, United Kingdom
    Arch Neurol 64:553-7. 2007
    ..To define the molecular basis of the autosomal dominant progressive external ophthalmoplegia and parkinsonism in a large family with a dominantly transmitted multiple mitochondrial DNA deletion disorder...
  83. ncbi Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study
    Jan Linder
    Department of Neurology, University Hospital, Umea, Sweden
    Mov Disord 25:341-8. 2010
    The differential diagnosis of parkinsonian disorders is difficult, especially early in the course of the diseases. The clinical subtypes of Parkinson's disease (PD) have not so far been described in newly diagnosed patients...
  84. ncbi Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism
    David R Williams
    The Queen Square Brain Bank for Neurological Disorders, University College London, UK
    Brain 128:1247-58. 2005
    ..The different tau isoform deposition in the basal pons suggests that this may ultimately prove to be a discrete nosological entity...
  85. ncbi Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes
    Ana M Catafau
    Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain
    Mov Disord 19:1175-82. 2004
    ..Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of (123)I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients...
  86. pmc Differential interaction of the E3 ligase parkin with the proteasomal subunit S5a and the endocytic protein Eps15
    Susan S Safadi
    Department of Biochemistry, The University of Western Ontario, London, Ontario N6A 5C1, Canada
    J Biol Chem 285:1424-34. 2010
    ..These results show that the parkin Ubld uses differential surfaces to recruit UIM regions from the S5a proteasomal subunit compared with Eps15 involved in cell signaling...
  87. ncbi Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions
    Edmar Miyoshi
    Laboratorio de Fisiologia e Farmacologia do Sistema Nervoso Central, Departamento de Farmacologia, Universidade Federal do Parana, C P 19 031, 81 531 990 Curitiba PR, Brazil
    Brain Res Bull 58:41-7. 2002
    ..Some parallels between the memory deficits in these SNc-lesioned rats and Parkinson's disease patients are also discussed...
  88. ncbi Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG)
    Felix Geser
    Clinical Department of Neurology, Innsbruck Medical University, Austria
    Mov Disord 21:179-86. 2006
    ..Our data contribute to the ongoing validation process of UMSARS, and they facilitate the planning and implementation of future neuroprotective intervention trials...
  89. pmc GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism
    Michelle Smeyne
    Department of Developmental Neurobiology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Proc Natl Acad Sci U S A 104:1977-82. 2007
  90. ncbi Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo
    Anthony C Vernon
    Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Campus, London, UK
    J Neurochem 103:1075-91. 2007
  91. ncbi Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism
    Corinne Beurrier
    Institut de Biologie du Developpement de Marseille Luminy, UMR 6216 CNRS Université de la Méditerranée, Marseille, France
    FASEB J 23:3619-28. 2009
    ..Finally, systemic administration of LSP1-2111 counteracts haloperidol-induced catalepsy, opening promising perspectives for the development of antiparkinsonian therapeutic strategies focused on orthosteric mGlu4-receptor agonists...
  92. ncbi Description of Parkinson's disease as a clinical syndrome
    Stanley Fahn
    Department of Neurology, Columbia University College of Physicians Surgeons, New York, New York 10032, USA
    Ann N Y Acad Sci 991:1-14. 2003
    ..Nonmotor symptoms (depression, lack of motivation, passivity, and dementia) are common. As the disease progresses, even motor symptoms become intractable to therapy. No proven means of slowing progression have yet been found...
  93. ncbi Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system
    Ranjita Betarbet
    Center for Neurodegenerative Disease, Center for Neurodegenerative Diseases, Whitehead Biomedical Research Building, 615 Michael Street, Atlanta, GA 30322, USA
    Neurobiol Dis 22:404-20. 2006
  94. ncbi ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
    A Di Fonzo
    Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
    Neurology 68:1557-62. 2007
    ..To assess the prevalence, nature, and associated phenotypes of ATP13A2 gene mutations among patients with juvenile parkinsonism (onset <21 years) or young onset (between 21 and 40 years) Parkinson disease (YOPD)...
  95. pmc Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability
    Lucio Santoro
    Department of Neurological Sciences, University of Naples Federico II, Naples, Italy
    Neurogenetics 12:33-9. 2011
  96. ncbi Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study
    Klaus Seppi
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Neuroimage 31:240-5. 2006
  97. ncbi Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients
    M Plotkin
    Klinik fur Strahlenheilkunde, Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin, Germany
    J Neural Transm 112:677-92. 2005
    ..IBZM SPECT is useful to approve the diagnosis of PSP and MSA although a normal finding cannot exclude an atypical PS. IBZM SPECT seems to be of restricted value in CBD...
  98. ncbi Autosomal recessive parkinsonism
    Vincenzo Bonifati
    Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
    Parkinsonism Relat Disord 18:S4-6. 2012
    ..Yet, it is expected that other monogenic forms of parkinsonism will be identified in the future, as mutations in the above-mentioned genes are not found in other patients with similar phenotypes...
  99. ncbi Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy
    Christian Brenneis
    Department of Neurology, University Hospital, Innsbruck, Austria
    Mov Disord 18:1132-8. 2003
    ..Further studies are required to determine clinical and/or subclinical correlates of cortical atrophy in MSA-P...
  100. pmc PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1
    Julia W Pridgeon
    Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia, United States of America
    PLoS Biol 5:e172. 2007
    ..Our findings suggest a novel pathway by which PINK1 phosphorylates downstream effector TRAP1 to prevent oxidative-stress-induced apoptosis and implicate the dysregulation of this mitochondrial pathway in PD pathogenesis...
  101. ncbi Proteomic profiling of cerebrospinal fluid in parkinsonian disorders
    Radu Constantinescu
    Institute of Neuroscience and Physiology, Department of Neurology, The Sahlgrenska Academy at the University of Gothenburg, 413 45 Goteborg, Sweden
    Parkinsonism Relat Disord 16:545-9. 2010
    Parkinson's disease (PD) and atypical parkinsonian disorders (APD), including multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), are a group of neurodegenerative diseases sharing many ..

Research Grants62

    PAUL GARRIS; Fiscal Year: 2005
    ..Moreover, L-DOPA is associated with adverse side effects after extended use, apparently due to non-physiological dopamine replacement. However, how L-DOPA acts on dopaminergic signaling is not completely established. ..
    Richard Smeyne; Fiscal Year: 2009
    ..This identification of GSTp2 as a candidate gene could also lead to the identification of diagnostic measures and point to potential therapies for early intervention in this devastating illness. ..
  3. Multimodal MRI markers of nigrostriatal pathology in Parkinson's disease
    Xuemei Huang; Fiscal Year: 2013
  4. A Tonically Active Network in the Neostriatum
    Charles J Wilson; Fiscal Year: 2013
    ..These experiments will reveal mechanisms promoting synchronization that may be points of action of dopaminergic depletion and possible targets for future anti-parkinsonian therapies. ..
    DENNIS WILLIAM DICKSON; Fiscal Year: 2013
    ..disease (PD) and a focus on the clinical genetics of familial Parkinsonism, a large brain bank of Parkinsonian disorders and strong institutional commitment to PD research and education...
  6. BradyXplore: Bradykinesia Feature Extraction System
    DUSTIN ALLEN HELDMAN; Fiscal Year: 2010
    ..Idiopathic Parkinson's disease (PD) and other parkinsonian disorders affect millions of people...
  7. Understanding the role of MAPT in Parkinsonian disorders
    Owen A Ross; Fiscal Year: 2013
    ..analyses suggest that different genetic variants on the MAPT H1 haplotype associate with each of these parkinsonian disorders. It currently remains unclear which variation at the MAPT locus is responsible for the risk and what is ..
  8. Ontology-based multiscale investigation of human neurological disease models
    Maryann E Martone; Fiscal Year: 2010
    ..To help unravel the multifaceted dimensions of diseases such as Parkinsonian disorders and cerebral ischemia, we describe a formal system for representing the characteristics of human ..
  9. Large Scale Biomarker Discovery and Validation for Parkinsons Disease
    Jing Zhang; Fiscal Year: 2013
    ..proteins are altered in PD patients, none discovered so far are specific enough to differentiate between parkinsonian disorders, diagnose PD at early stages, or trace its progression...
  10. Functional Characterization of LRRK2 Knock-out and Knock-in Mouse Models
    Heather L Melrose; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: Mutations in the gene LRRK2 cause Parkinson Disease. This proposal aims to use animal models to study the biological manner in which LRRK2 mutations exert their pathogenic effects. ..
  11. PINK1 Regulation of Neuronal and Mitochondrial Homeostasis
    Charleen T Chu; Fiscal Year: 2013
    ..Achieving the goals of this project to obtain a better understanding of PINK1 regulation of autophagy and mitochondria will provide insight into new therapeutic strategies to reduce neuronal dysfunction in PD. ..
    Charles J Wilson; Fiscal Year: 2010
    ..abstract_text> ..
  13. Basal Ganglia Neurophysiology during DBS in Rats
    Jing Yu Chang; Fiscal Year: 2006
    ..The goal of this study is to explore the basic neural mechanism underlying the therapeutic effects of DBS and the knowledge obtained form this study will help us to improve the clinical treatment of PD with DBS method. ..
  14. Parkin function: Regulation of members of synaptotagmin
    Duong Huynh; Fiscal Year: 2009
    ..The ultimate goal of this proposal is to elucidate how parkin deficiency results in dopaminergic dysfunction and cell death in Parkinson's disease. ..
  15. Effects of DBS on sensorimotor processes
    Jing Yu Chang; Fiscal Year: 2005
    ..This research will be done primarily at Peking University in China as an extension of NIH grant R01-NS43441. ..
  16. Biochemical Characterization of Parkin
    Kiran Madura; Fiscal Year: 2003
    ..iv). Our long-term objective is to characterize the ubiquitination of a-Syn and other physiological substrates by Parkin. ..
  17. Cortical regulation of striatal dendritic spine loss in parkinsonism
    BONNIE GARCIA; Fiscal Year: 2009
    ..The studies proposed address one potential mechanism involved in poor symptomatic response late to dopamine replacement treatment late in the course of Parkinson's disease and related parkinsonian syndromes. ..
  18. The Role of Parkin in the Synaptic Vesicle Cycle
    Kristen Willeumier; Fiscal Year: 2007
    ..We are therefore testing the hypothesis that parkin is involved in regulating the number and/or functionality of synaptic vesicles through its interaction with proteins at the presynaptic nerve terminal. ..
    MICHEAL PHILLIPS; Fiscal Year: 2002
    ..The present proposal represents a first step toward the development of such a gold standard. ..
  20. Ubiquitination/Receptor Signaling--Regulation by Parkin
    Benjamin Wolozin; Fiscal Year: 2004
    ..abstract_text> ..
  21. Gene Therapy, Neural Grafts & Parkinson's Disease
    DAVID YUREK; Fiscal Year: 2005
    ..These studies will also determine if combinations of viral vectors expressing different neurotrophic factors can be used to improve the therapeutic effects of dopamine grafts. ..
    Brad Racette; Fiscal Year: 2006
    ..abstract_text> ..
  23. Epidemilogy of Parkinsonism in Welders
    Brad A Racette; Fiscal Year: 2011
    ..The cohort assembled will provide unique opportunities for future research projects into gene-environment interactions and exposure related neuroimaging changes. ..
    Robert E Burke; Fiscal Year: 2010
    ..abstract_text> ..
  25. Neurobiologic Study of Psychological Distress & Dementia
    Robert S Wilson; Fiscal Year: 2010
    John Nutt; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  27. Mechanisms of Bax-mediated cell death in the MPTP model
    Serge Przedborski; Fiscal Year: 2007
    ..Collectively, the proposed studies should shed light on the molecular mechanisms of neurodegeneration in PD and help to identify new molecular targets for therapeutic intervention. ..
  28. Second International Brainstorming Meeting on Parkinson Disease: Nosology
    Irene Litvan; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  29. Genetic and Environmental Risk Factors for PSP
    Irene Litvan; Fiscal Year: 2010
    ..The use of the NINDS cell repository for genetic banking will also allow DNA sample sharing with other investigators. ..
    Serge Przedborski; Fiscal Year: 2003
    Serge Przedborski; Fiscal Year: 2002
    ..This proposal contains a comprehensive set of experiments, which should provide important insights into the role of NO in MPTP toxicity. It should also shed light on the mechanism(s) of neurodegeneration in PD. ..
  32. Effect of enriched environment on ALS neurodegeneration
    Serge Przedborski; Fiscal Year: 2005
    ..This development/exploratory project offers an high-risk/high-yield set of studies which may demonstrate, in an original way, how environment may impact on the occurrence and the progression of ALS. ..
  33. Characterization of a novel metal ion permeable channel
    Meredith Hermosura; Fiscal Year: 2006
    ..These mutations will be then engineered in the expression system to assess resulting alterations in channel function. ..
  34. Basal ganglia discharge patterns in parkinsonism
    Thomas Wichmann; Fiscal Year: 2005
    Wayne Cass; Fiscal Year: 2005
  36. Mapping a Gene for Parkinsons Disease in Norway
    Matthew Farrer; Fiscal Year: 2005
    ..We will explore the utility of haplotype tagging (htSNPs) to capture disease-association (Aim 3). Identification of the PD-susceptibility gene will be confirmed in US samples and functionally assessed. ..
  37. Changes in nicotinic receptors in parkinsonian animals
    JENNIFER KULAK; Fiscal Year: 2004
    ..abstract_text> ..
  38. Synaptic Proteins, Trophic Factors and Neurodegeneration
    Gloria Meredith; Fiscal Year: 2004
    ..The findings of this research should shed light on target areas where neuroprotection strategies can be implemented. ..
    Charleen Chu; Fiscal Year: 2004
    Marina Emborg; Fiscal Year: 2003
    ..These studies will serve as the preclinical foundation to determine whether this in vivo method to deliver these potent trophic factor and antiapoptotic genes will be suitable for testing in patients with PD. ..
  41. Genetic Analysis of Tau H1 in Parkinsonism
    Matthew Farrer; Fiscal Year: 2006
    ..abstract_text> ..
  42. Function of dopamine in the primate substantia nigra
    Thomas Wichmann; Fiscal Year: 2009
    ..g., transplantation of ventral mesencephalic tissue) may act through local release of dopamine. ..
    John Kane; Fiscal Year: 2001
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  44. Regulation of PTEN-induced kinase 1 (PINK 1)
    Charleen Chu; Fiscal Year: 2007
    ..In addition, a group of immunochemical and molecular reagents will have been created that can facilitate the work of other investigators studying mechanisms of Parkinson's and related diseases. [unreadable] [unreadable]..
  45. Influence of subthalamic nucleus on striatal dopamine
    Thomas Wichmann; Fiscal Year: 2004
    ..These studies will provide insight into the role of the STN-SNc interaction under normal and parkinsonian conditions and will help to understand the mechanisms of action of neurosurgical treatments aimed at SIN in parkinsonian patients. ..
    DONALD REDMOND; Fiscal Year: 2004
    ..The results will also advance understanding of useful methods for studying and treating a broad range of neurodegenerative, genetic, and traumatic conditions of the nervous system. ..
  47. Improving neural graft function in parkinsonian monkeys.
    DONALD REDMOND; Fiscal Year: 2007
    ..abstract_text> ..
  48. GDNF Delivery to MPTP Monkeys by EIAV lentivirus and AAV
    DONALD REDMOND; Fiscal Year: 2008
    ..These studies aim to provide the necessary data to initiate successful clinical trials in Parkinson's patients at the earliest possible time. ..
  49. Calcitriol-Induced Restoration of Dopamine in a Model of Parkinson's Disease
    Wayne Cass; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  50. Mechanisms underlying reward-related synaptogenesis
    Gloria E Meredith; Fiscal Year: 2010
    ..abstract_text> ..
  51. Models of Familial Parkinson's Disease: PINK1
    Ted Dawson; Fiscal Year: 2006
  52. GM1 Ganglioside Effects on Parkinson's Disease
    Jay Schneider; Fiscal Year: 2007
    ..Working hypothesis: Long-term GM1 use will stabilize symptoms or slow the progression of symptoms in PD patients and this may be accompanied by reduced loss of striatal DA terminals over time. [unreadable] [unreadable]..
  53. Nicotinic and neuroprotection in a parkinson mouse model
    Maryka Quik; Fiscal Year: 2007
    ..This may allow for the design of neuroprotective strategies for PD, a disorder for which only symptomatic treatment is currently available. ..
  54. Nicotine and Cognition in Parkinsonism
    Jay Schneider; Fiscal Year: 2008
    ..Information obtained from these studies will hopefully lead to more efficient design of nicotinic therapeutics for patients with a variety of cognitive disorders. ..
  55. Economic and Policy Analyses in Geriatric Disease
    EKATERINA NOYES; Fiscal Year: 2006
    ..The model and analytical approaches acquired by the candidate during her training will be used later to develop a decision analytical model describing geriatric depression. ..
    Rosemarie Bowler; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  57. Calcitriol and Methamphetamine Neurotoxicity
    Wayne Cass; Fiscal Year: 2008
    ..Furthermore, if calcitriol is effective, it could have therapeutic applications in other disease processes where there is a loss of monoamine neurons, such as in Parkinson's disease. [unreadable] [unreadable] [unreadable]..
    Walter Rocca; Fiscal Year: 2009
    ..abstract_text> ..
  59. TH and GTPCHI gene therapy for Parkinson's disease
    Jeffrey H Kordower; Fiscal Year: 2010
    ..These studies will determine the safety and efficacy of gene delivery of LDOPA and determine whether this approach is appropriate for clinical trials. ..